A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Conditions: Prostatic Neoplasms Interventions: Drug: Novel hormonal therapy Sponsors: Pfizer; Astellas Pharma Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 9, 2023 Category: Research Source Type: clinical trials
Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients
Conditions: Recurrent Prostate Cancer Sponsors: Power Life Sciences Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials
All-in-One Prostate Cancer Staging With MRI
Conditions: Prostate Cancer Interventions: Diagnostic Test: Prostate Cancer Patients Sponsors: European Institute of Oncology; Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia; Azienda Ospedaliera Universitaria Integrata Verona Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Conditions: Metastatic Castration-resistant Prostate Cancer Interventions: Drug: BMS-986460 Sponsors: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials
Longitudinal Advanced Prostate Cancer Cohort (LAPCC)
Conditions: Prostate Carcinoma; Stage IV Prostate Cancer American Joint Committee on Cancer v8 Interventions: Other: Non-Interventional Study Sponsors: University of Southern California; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
Conditions: Prostate Cancer Interventions: Drug: 177Lu rhPSMA-10.1; Drug: Degarelix Sponsors: M.D. Anderson Cancer Center; AVEO Pharmaceuticals, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
Conditions: Cancer; Solid Tumor; Thromboembolism; Cardiovascular Diseases; Immune System Diseases; Inflammatory Diseases; Colon Cancer; Breast Cancer; Prostate Cancer; Hepatocellular Carcinoma; Lung Cancer; Chemotherapy; Immunotherapy Interventions: Drug: Palbociclib; Drug: Rivaroxaban; Genetic: SNP Sponsors: Lebanese University; Haykel Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
Conditions: Prostate Adenocarcinoma; Stage II Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8 Interventions: Drug: Apalutamide; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Other: Gallium Ga 68 Gozetotide; Radiation: MRI-guided Stereotactic Body Radiation Therapy; Procedure: Multiparametric Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Other: Questionnaire Administration Sponsors: Jonsson Comprehensive Cancer Center; Janssen Scientific Affairs, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study
Conditions: Prostate Cancer Interventions: Behavioral: CARE-PC Web-Based Application Sponsors: Vivek Narayan; National Comprehensive Cancer Network Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Conditions: Breast Cancer; Ovarian Cancer; Pancreas Cancer; Prostate Cancer; BRCA1 Mutation; BRCA-Mutated Ovarian Carcinoma; BRCA-Associated Breast Carcinoma; HRD Positive Advanced Ovarian Cancer Interventions: Drug: TNG348; Drug: Olaparib Sponsors: Tango Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Conditions: Advanced Prostate Cancer; Metastatic Prostate Cancer; Metastatic Prostate Neuroendocrine Carcinoma Interventions: Drug: 18F-fluciclovine; Device: PET/CT Sponsors: Dana-Farber Cancer Institute; Blue Earth Diagnostics, Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials
Phase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate Cancer
Conditions: Prostate Cancer Interventions: Drug: HRS-9815 injection Sponsors: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials
Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)
Conditions: Oligometastatic Prostate Cancer Sponsors: Centro di Riferimento Oncologico - Aviano Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
Conditions: Prostate Cancer Interventions: Drug: Docetaxel; Drug: ADT; Drug: Abiraterone Sponsors: Northwestern University; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer Interventions: Drug: DFMO; Drug: testosterone cypionate; Drug: Luteinizing hormone-releasing hormone (LHRH) analogue; Drug: Enzalutamide Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Panbela Therapeutics; Prostate Cancer Foundation; United States Department of Defense Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
